title: Update on vaccination of cattle and wildlife populations against tuberculosis.
abstract: In this review, the status of vaccination strategies to reduce bovine tuberculosis of cattle and wildlife reservoirs of the disease is discussed, with a focus on recent developments. Recent work in vaccines to protect humans against tuberculosis has been followed by a similar surge of interest in developing vaccines against bovine tuberculosis. The human vaccine, bacille Calmette-Guérin (BCG) affords protection against tuberculosis in cattle, but this protection is variable. In addition, vaccination with BCG compromises control strategies based on skin testing animals. In general, no single vaccine approach has shown itself to be significantly superior to BCG alone, however, vaccine combinations of BCG and vaccinating moiety such as adjuvanted subunit, virus vectored or DNA vaccines have been shown to induce protection superior to that achieved by BCG alone. Vaccinating wildlife species against tuberculosis is also an area which has been subjected to scrutiny. Recent work has focused on vaccinating wildlife orally, via the use of BCG formulated in baits consumed by these species. Results from trials in a number of animal species indicate that oral BCG vaccination can reduce disease severity following experimental challenge with Mycobacterium bovis and in a recent field trial, oral BCG vaccination was shown to prevent infection of wild possums following natural exposure to M. bovis. In conclusion, recent studies in cattle and wildlife have demonstrated the practicality and effectiveness of vaccinating animals against tuberculosis and provide much impetus for future use of vaccines.
authors.affiliation: AgResearch, Hopkirk Research Institute, Palmerston North, New Zealand. bryce.buddle@agresearch.co.nz
authors.forename: Bryce M
authors.initials: BM
authors.lastname: Buddle
authors.forename: D Neil
authors.initials: DN
authors.lastname: Wedlock
authors.forename: Michel
authors.initials: M
authors.lastname: Denis
authors.forename: H Martin
authors.initials: HM
authors.lastname: Vordermeier
authors.forename: R Glyn
authors.initials: RG
authors.lastname: Hewinson
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000284:Administration, Oral; D000818:Animals; D000835:Animals, Wild / Q000276:immunology*; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000276:immunology; D002417:Cattle / Q000382:microbiology*; D009163:Mycobacterium bovis / Q000276:immunology; D014380:Tuberculosis, Bovine / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000639:trends / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA